Bio-Heart Bio to Launch Clinical Study for Rapamycin Drug-Eluting Balloon in Japan
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that it will initiate...
Bio-Heart Bio Receives Ethical Approval for Iberis RDN System in Hainan
China-based Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced receiving ethical approval from...
BeiGene’s Brukinsa Receives EC Approval for CLL Treatment
China-based biotech BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving marketing approval...
Zhangjiang AI New Drug R&D Alliance Expands with New Members
The Zhangjiang AI New Drug R&D Alliance has welcomed new participants, including Regor Therapeutics, Roche,...
Subtle Medical Secures Series B Funding for AI-Powered Medical Imaging
Subtle Medical, an Artificial Intelligence (AI)-empowered medical imaging company based in Guangdong, has reportedly raised...
Hengrui Pharmaceuticals Receives Clinical Trial Approvals for Three New Drugs
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving clinical trial approvals for three in-house...
Rainsure Scientific Secures Series C1 Funding for Digital PCR Development
Rainsure Scientific, a Suzhou-based developer of digital PCR instruments and RUO detection kits, has reportedly...
CSPC Pharma’s rhTNK-tPA Accepted for Review by NMPA for Stroke Indication
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that a supplementary market filing for...
Asia Pacific Medical Group Secures Series A Funding for Hospital Expansion
Private healthcare group Asia Pacific Medical Group (APMG) has raised “hundreds of millions” of renminbi...
Haisco’s HSK31858 Gains Ethical Approval for Phase II Study in NCFBE
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its drug candidate HSK31858...
CANbridge’s CAN106 Receives Orphan Drug Designation for Myasthenia Gravis
China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) has announced receiving Orphan Drug Designation...
HitGen Partners with Guangzhou AIChemEco for Automated Synthesis Technology
China-based HitGen Inc. (SHA: 688222) has announced a partnership with compatriot firm Guangzhou AIChemEco. The...
Harbour BioMed Establishes Nona Biosciences for Next-Generation Antibody Development
Harbour BioMed (HKG: 2142), a biotech company with operations in the Netherlands, the United States,...
Novartis Considers Sale of Non-Core Units to Fund Innovation
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly considering the sale of certain ‘non-core’...
Sequanta Technologies Partners with Illumina to Introduce NovaSeq X Series
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, has entered into...
Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug...
MicroTech Medical Plans IPO on Shanghai’s STAR Market
China-based diabetes specialist MicroTech Medical (Hangzhou) Co., Ltd (HKG: 2235) has announced plans to conduct...
Kelun Pharma’s SKB264 Advances to Phase II Study for NSCLC
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody drug conjugate...
Gracell’s FasTCAR Platform Wins Fierce Life Sciences Innovation Award
China-based Gracell Biotechnologies Inc’s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this...
Walvax Biotechnology Expands Manufacturing Partnership with Etana for PCV and HPV Vaccines
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with...